Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 2, 2006, Pages 255-257

  Moreau, C ^a   Devos, D ^a,b   Brunaud Danel, V ^a   Defebvre, L ^a   Perez, T ^a   Destee A ^a   Tonnel, A B ^b   Lassalle, Ph ^c   Just, N ^c  

^a MENRT   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HYPOXEMIA; HYPOXIA; MALE; MOTOR NEURON DISEASE; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANOXEMIA; CIRCADIAN RHYTHM; FEMALE; GENE EXPRESSION; HUMANS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROLOGIC EXAMINATION; OXYGEN; REFERENCE VALUES; STATISTICS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 32344449557     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.070904     Document Type: Article

References (14)

1. Chio A, Benzi G, Dossena M, et al. Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players. Brain 2005;128:472-6.
2. Lyall RA, Donaldson N, Polkey MI, et al. Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001;124:2000-13.
3. Lambrechts D, Storkebaum E, Morimoto M, et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motorneurons against ischemic death. Nat Genet 2003;34:383-94.
4. Oosthuyse B, Moons L, Storkebaum E, et al. Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nat Genet 2001;28:131-8.
5. Van den Bosh L, Storkebaum E, Vleminckx V, et al. Effects of VEGF on motor neuron degeneration. Neurobiol Dis 2004;17:21-8.
6. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motor neuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Naf Neurosci 2005;8:85-92.
7. Zheng C, Nennesmo I, Fadeel B, et al. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2004;56:564-67.
8. Devos D, Moreau C, Lassalle P, et al. Low levels of VEGF in CSF from early ALS patients. Neurology 2004;62:2127-9.
9. Hukins CA, Hillman DR. Daytime predictors of sleep hypoventilation in Duchenne muscular dystrophy. Am J Respir Crit Care Med 2000;161:166-70.
10. Nygren I, Larson A, Johansson A, et al. VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. Neuroreport 2002;13:2199-201.
11. Ilzecka J. Cerebrospinal fluid VEGF in patients with ALS. Clin Neurol Neurosurg 2004;106:289-93.
12. Shiote M, Nagano I, Ilieva H, et al. Reduction of a vascular endothelial growth factor, fetal liver kinase 1, by antisense oligonucleotides induces motor neuron death in rat spinal cord exposed to hypoxia. Neuroscience 2005;132:175-8.
13. Schulz R, Hummel C, Heineman S, et al. Serum levels of VEGF are elevated in patients with obstructive sleep apnea and severe nighttime hypoxia. Am J Respir Crit Care Med 2002;165:67-70.
14. Pinto AC, Evangelista T, Carvalho M, et al. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in a controlled trial. J Neurol Sci 1995;129(suppl):19-26.